atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financial Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Medical Officer (CMO).
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
atai Life Sciences’ Perception Neuroscience’s PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study
Perception Neuroscience, an atai Life Sciences biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data…
JOIN THE ATAI #INSIGHTNETWORK